TechGuru
Great post!
**Leronlimab, CLOVER, and ctDNA: The Science Is Becoming Harder to Ignore**
A 2026 systematic review involving 64 studies and more than 2,760 metastatic colorectal cancer patients found that favorable ctDNA changes during treatment were strongly associated with improved progression-free and overall survival.
Friends of Cancer Research's ctMoniTR initiative further supports the importance of early ctDNA reductions as indicators of potential treatment benefit.
**Now consider CLOVER's early findings:**
- Approximately **70% median ctDNA reduction** at 350 mg.
- Approximately **90% median ctDNA reduction** at 700 mg.
- **23 of 31 patients (74%)** with Week 8 scans demonstrated tumor shrinkage or stable disease.
- A potentially meaningful dose-response relationship.
These findings deserve attention, particularly in heavily pretreated metastatic colorectal cancer patients.
But there may be an even bigger story.
**Leronlimab targets CCR5**, a receptor involved in tumor progression, immune-cell trafficking, and the tumor microenvironment. Blocking CCR5 may help overcome mechanisms cancers use to evade immune attack and resist treatment.
That raises the possibility that leronlimab is doing more than helping control tumor growth—it may be changing the biological environment in which cancer survives.
And remember, **objective response rate (ORR) does not tell the entire story.** Patients can experience meaningful clinical benefits through prolonged disease stabilization and delayed progression without dramatic tumor shrinkage.
Early ctDNA reductions may provide important clues about those benefits before conventional imaging.
The critical next step is demonstrating that CLOVER's molecular responses translate into durable disease control and improved survival—and establishing leronlimab's contribution beyond the chemotherapy backbone.
**My takeaway:**
We have substantial early ctDNA reductions, encouraging preliminary imaging results, a potential dose-response signal, and independent scientific research supporting the prognostic importance of ctDNA.
That is a compelling reason for optimism, even though clinical benefit attributable to leronlimab remains to be proven.
**The real question isn't simply how many tumors shrink at Week 8. It's how long patients live and how long their disease remains controlled.**
If CLOVER connects these early molecular signals to durable clinical outcomes, the implications for leronlimab and CCR5-targeted cancer therapy could be significant.
**The science is giving us reasons to pay attention. Now we need the clinical outcomes to confirm the promise.**
Sources:
https://pmc.ncbi.nlm.nih.gov/articles/PMC12969389/
https://friendsofcancerresearch.org/ctdna/
Great post!
**Leronlimab, CLOVER, and ctDNA: The Science Is Becoming Harder to Ignore**
A 2026 systematic review involving 64 studies and more than 2,760 metastatic colorectal cancer patients found that favorable ctDNA changes during treatment were strongly associated with improved progression-free and overall survival.
Friends of Cancer Research's ctMoniTR initiative further supports the importance of early ctDNA reductions as indicators of potential treatment benefit.
**Now consider CLOVER's early findings:**
- Approximately **70% median ctDNA reduction** at 350 mg.
- Approximately **90% median ctDNA reduction** at 700 mg.
- **23 of 31 patients (74%)** with Week 8 scans demonstrated tumor shrinkage or stable disease.
- A potentially meaningful dose-response relationship.
These findings deserve attention, particularly in heavily pretreated metastatic colorectal cancer patients.
But there may be an even bigger story.
**Leronlimab targets CCR5**, a receptor involved in tumor progression, immune-cell trafficking, and the tumor microenvironment. Blocking CCR5 may help overcome mechanisms cancers use to evade immune attack and resist treatment.
That raises the possibility that leronlimab is doing more than helping control tumor growth—it may be changing the biological environment in which cancer survives.
And remember, **objective response rate (ORR) does not tell the entire story.** Patients can experience meaningful clinical benefits through prolonged disease stabilization and delayed progression without dramatic tumor shrinkage.
Early ctDNA reductions may provide important clues about those benefits before conventional imaging.
The critical next step is demonstrating that CLOVER's molecular responses translate into durable disease control and improved survival—and establishing leronlimab's contribution beyond the chemotherapy backbone.
**My takeaway:**
We have substantial early ctDNA reductions, encouraging preliminary imaging results, a potential dose-response signal, and independent scientific research supporting the prognostic importance of ctDNA.
That is a compelling reason for optimism, even though clinical benefit attributable to leronlimab remains to be proven.
**The real question isn't simply how many tumors shrink at Week 8. It's how long patients live and how long their disease remains controlled.**
If CLOVER connects these early molecular signals to durable clinical outcomes, the implications for leronlimab and CCR5-targeted cancer therapy could be significant.
**The science is giving us reasons to pay attention. Now we need the clinical outcomes to confirm the promise.**
Sources:
https://pmc.ncbi.nlm.nih.gov/articles/PMC12969389/
https://friendsofcancerresearch.org/ctdna/
5
